Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

4 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.

Tofacitinib trumps vedolizumab for short-term efficacy in ulcerative colitis

30 Jan 2020

Short-term efficacy appears to be higher with tofacitinib (TOF) than with vedolizumab (VDZ) in the treatment of patients with ulcerative colitis (UC), regardless of disease severity and previous biologics use, a recent study has shown.

This retrospective single-centre observation study included UC patients who initiated TOF (n=38) or VDZ (n=28) from May 2018 to May 2019. Short-term efficacy was evaluated by remission rate, defined as a partial Mayo score (pMayo) of 1 point, and response rate, defined as a pMayo 1 point or a decrease of 3 points, at 2 and 6 weeks after treatment initiation.

The authors also examined the clinical background factors contributing to the efficacy at 6 weeks and evaluated the side effects in the mean observation period (TOF: 133.6 days; VDZ: 74.6 days).

Clinical background factors were not significantly different between the TOF and VDZ groups in terms of clinical duration (10.7 vs 7.9 years), relapse-remission type (71.1 percent vs 64.3 percent) and all colitis type (63.2 percent vs 60.7 percent).

However, the TOF group had more severe UC (average pMAYO, 5.7 vs 4.0 points; p=0.002; average endoscopic Mayo score [eMayo], 2.58 vs 1.82; p=0.002; average UC endoscopic index of severity, 4.34 vs 2.71; p=0.001) and fewer bio-naive cases (23.7 percent vs 50.0 percent; p=0.027).

The remission rates were comparable at weeks 2 (23.7 percent vs 28.5 percent; p=0.654) and 6 (39.4 percent vs 32.1 percent; p=0.611), while the response rates were higher for the TOF group at weeks 2 (50.0 percent vs 35.7 percent; p=0.248) and 6 (63.2 percent vs 35.7 percent; p=0.027).

No serious side effects were reported. None of the patients in both groups discontinued treatment due to side effects.

“In the near future, further head-to-head study is required to extend these findings and determine the appropriate therapeutic options in terms of the mid- to long-term efficacy and safety,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

4 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.